{
    "clinical_study": {
        "@rank": "95607", 
        "arm_group": {
            "arm_group_label": "Contrast-enhanced ultrasound (CEUS)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The investigators primary aim is to increase chemotherapeutic drug uptake in inoperable\n      tumours\n\n      The specific sub-objectives of the studies are:\n\n        -  To quantify tumour sizes and relate it to the patient survival over time, dependent of\n           treatment method.\n\n        -  To evaluate and compare the toxic effects and safety of gemcitabine in combination with\n           US contrast agent under sonication with gemcitabine alone.\n\n        -  Develop and validate new ultrasound perfusion algorithms based on burst- replenishment\n           for diagnosis and monitoring of therapy.\n\n        -  To quantify gemcitabine and its main metabolites in plasma and in circulating\n           mononuclear cells before, during and after pancreatic sonication, and to quantify the\n           concentration of intracellular endogenous nucleotides in circulating mononuclear cells\n           at the same time points.\n\n        -  To assess plasma and tissue concentrations of gemcitabine, its main metabolites and\n           endogenous nucleotides in those patients where surgical resection can be performed on\n           standard clinical indications."
        }, 
        "brief_title": "Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "detailed_description": {
            "textblock": "The primary outcome is monitor for toxicity effect for the combination therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with inoperable pancreatic cancer (ICD-10 C25.0-3) at the Department of\n             Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to\n             participate\n\n        Exclusion Criteria:\n\n          -  Patient participated in an investigational study within 30 days prior to study entry\n             (or, if longer, within five half-lives of the last dose of any investigational drug).\n\n          -  Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.\n\n          -  Patient has a history of cardiovascular ischemia, acute myocardial infarction or\n             unstable angina within 3 months prior to study entry.\n\n          -  Patient has a history of any psychiatric disorder or cognitive impairment that would\n             interfere with participation in the study.\n\n          -  Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.\n\n          -  Patient requires dialysis or has severely impaired renal function, defined as a serum\n             creatinine > 180 mmol/L at the Screening Visit.\n\n          -  Patient has severe impairment of liver function, defined as a serum albumin level \u2264\n             25 g/L and/or a Protrombin Time INR > 2.3 (or APTT > 6 seconds above the upper limit\n             of normal) at the Screening Visit.\n\n          -  Patient is pregnant or is breast-feeding.\n\n          -  Patient is allergic to or intolerant of gemcitabine\n\n          -  Patient is allergic to or intolerant of SonoVue\u00ae BRACCO ultrasound contrast agent\n\n          -  Any reason why, in the opinion of the investigator, the patient should not\n             participate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674556", 
            "org_study_id": "2011/1601"
        }, 
        "intervention": {
            "arm_group_label": "Contrast-enhanced ultrasound (CEUS)", 
            "description": "Gemcitabine in combination with ultrasound (US) contrast agent under sonication", 
            "intervention_name": "Gemzar", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pancreatic", 
            "cancer", 
            "adenocarcinoma", 
            "Ultrasound", 
            "CEUS"
        ], 
        "lastchanged_date": "July 8, 2013", 
        "location": {
            "contact": {
                "email": "georg.dimcevski@helse.bergen.no", 
                "last_name": "Georg Dimcevski"
            }, 
            "facility": {
                "address": {
                    "city": "Bergen,", 
                    "country": "Norway"
                }, 
                "name": "Haukeland University Hospital"
            }, 
            "investigator": {
                "last_name": "Georg Dimcevski", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "1", 
        "official_title": "Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification", 
        "other_outcome": {
            "measure": "tumor size", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "overall_contact": {
            "email": "Georg.dimcevski@helse-bergen.no", 
            "last_name": "Georg Dimcevski"
        }, 
        "overall_official": {
            "affiliation": "Haukeland University Hospital", 
            "last_name": "Georg Dimcevski", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Norway: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate and compare the toxic effects and safety of gemcitabine in combination \twith US contrast agent under sonication with gemcitabine alone.", 
            "measure": "Toxic effects and safety of gemcitabine in combination with US contrast agent under sonication with gemcitabine alone.", 
            "safety_issue": "Yes", 
            "time_frame": "Two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "tumor size", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "source": "Haukeland University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Haukeland University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}